Researchers ecstatic after catching rare glimpse of critically endangered creature in nature refuge: 'It's very gratifying'
A tussle between two wild animals caught on a trail camera revealed happy news about an elusive species–and ended happily for both critters.
In hours of footage captured at Richard Underwood Nature Refuge in Australia, a northern hairy‑nosed wombat tried to take on a short‑beaked echidna, revealing exciting conservation updates for researchers about conservation efforts for the endangered wombat species, according to a report from Earth.com.
The researchers noted that the young wombat looked healthy, with a smooth coat and sturdy build, suggesting plenty of foraging opportunities and low-stress conditions.
"It's very gratifying to know that one of the world's most critically endangered animals is doing well and breeding within the safety of the fenced area," Andy Howe of the Australian Wildlife Conservancy told the outlet.
Only 400 northern hairy‑nosed wombats live in the wild currently. In 2009, a group of 15 wombats was moved to the park as part of conservation efforts. According to the researchers, the junior wombat's appearance on camera confirmed that a second generation is doing well without hand-feeding from humans.
Wombats are important to the health of the soil in the ecosystem thanks to their burrowing, which brings important nutrients to the surface and helps mix organic matter and seedlings, according to WIRES (Wildlife Information, Rescue and Education Service). Their burrows also provide shelter for other species, making them crucial to more species during increasingly intense heatwaves in the Outback.
In their report, the researchers noted the importance of trail cameras in helping monitor wombat health by letting "ecologists confirm pouch emergence dates, monitor health, and detect any intruding wild dogs before disaster strikes," Earth.com explained.
Scientists around the world have been able to track more and more species with trail cameras, making hopeful discoveries like the return of the pangolin in India, wolves in North America, and rare otter behavior in Israel.
As for the fight between the wombat and the echidna, for the spiny-backed marsupial, it was hardly a fight at all, as the wombat was all bluff and the echidna just kept walking by. "It's a nervous wombat and a happy echidna," biologist Tim Flannery of the Australian Museum told the outlet.
Do you think America does a good job of protecting its natural beauty?
Definitely
Only in some areas
No way
I'm not sure
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Incredible Australian footage reveals new predator killing city rats
Incredible footage has captured the moment a 1kg native Australian predator attacked a 200g invasive black rat. The aggressor in the video is a rakali, a semi-aquatic native rodent species that's learned how to attack other feral species, including carp and poisonous cane toads. Jenna Bytheway, a senior researcher at Sydney University, led an investigation into the footage, telling Yahoo News she is excited to see the rakali is showing clear signs of actually hunting the smaller rodent as prey. 'Rakali tend to be ambush predators when they're hunting on land or at the water's edge," she said. "In the video, you see it sitting and waiting, and then ambushing. And that suggests it may have been a predatory attack.' There's little chance that a fixed trail camera would have caught an attack like this unless it was happening regularly. And while it's not known if the rakali caught the black rat, a simple attack could impact the abundance of the pests. 'Given the size and aggressive nature of the rakali compared to the black rat, the impacts and the effects of fear can also reduce the number of rats in an area and change how they behave,' Bytheway said. Could rakali help fight $390 billion invasive species problem? The interaction was captured on the banks of Sydney Harbour in 2011 and then archived. But the researchers decided it was time to release the footage now because rakali are facing mounting threats, including the rapid spread of rat lungworm through Queensland and NSW, which originated in southeast Asia and is carried by introduced rats and snails. Habitat destruction, pollution, and poisoning from common household baits commonly sold at hardware stores and supermarkets are also killing off this important species. Despite being found in populated areas along Australia's east coast, very little is known about rakali. And more research would be required to determine how widespread their impact is on invasive species. CSIRO research indicates invasive species have cost Australia more than $390 billion in the last 60 years to 2021. Rats alone continue to cause hundreds of millions of dollars in damage to the agriculture sector every year. But using second-generation anticoagulant rodenticides to tackle them is killing off the nation's wildlife, including owls and eagles. And scientists are increasingly looking towards natural methods of control, like attracting owls to paddocks to eat rats. Incredible discovery at market after common fish purchase Wild photo shows hidden danger in mud Calls for action as road safety project remains incomplete after five years Bytheway is hopeful that one day, rakali could play a role too. But before that, funding would be required to confirm that what happened in the video wasn't a unique occurrence. 'If we can conserve rakali as a native species, not only will they be performing a vital role in the environment, they might be reducing the impacts of invasive species like black rats, cane toads and invasive fish. It's a win-win for everyone,' Bytheway said. The research has been published in the journal Australian Mammalogy and featured in The Conversation. Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Yahoo
13 hours ago
- Yahoo
Rakali ambushes invasive black rat
The footage was taken in 2011 by a trail camera on Sydney Harbour. Source: Australian Mammalogy/Sydney University
Yahoo
a day ago
- Yahoo
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (efti), have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 taking place 17-21 October in Berlin, Germany. A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company's pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. Details of the presentations are as follows: Title: EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma Presenter: Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Session Category: Proffered Paper Session Title: Sarcoma Presentation #: 2686O Date and Time: Sunday, 19 October 2025 at 16:30 – 18:00 PM CET Title: Eftilagimod alpha (soluble LAG-3 protein) combined with 1st line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC) –Updates from INSIGHT-003 (IKF614) Presenter: Dr. med. Akin Atmaca, Department of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany Session Category: Poster Session Title: NSCLC, metastatic Presentation #: 1857P Date and Time: Saturday, 18 October 2025 at 12:00 – 12:45 PM CET Title: TACTI-004, a double-blinded, randomised phase 3 trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC Presenter: Prof. Dr. med. Hans-Georg Kopp, Robert Bosch Hospital, Stuttgart, Germany Session Category: ePoster Session Title: NSCLC, metastatic Presentation #: 2086eTiP Proffered Papers at ESMO are oral presentations of original data of superior quality, followed by expert discussion and perspectives. Abstracts will be made available on the ESMO website on 13 October 2025 at 00.05 CET. The posters will be available on the Posters & Publications section of Immutep's website after their presentations. About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;
